According to a study last year at Fox Chase Cancer Center, men whose prostate specific antigen (PSA) rise within 18 months of having primary radiotherapy are more likely to develop advanced prostate cancer and die of their disease. […]
A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer (CRPC). The study enrolled sixty-nine with CRPC. Docetaxel dosage was downed to 25 mg/m2 on days 1 and 8 every [...]
We know that approximately one-third of all men who elect to have a radical prostatectomy for localized prostate cancer will ultimately experience a biochemical (PSA) recurrence. Researchers at the Department of Urology, Loyola University Medical Center, Maywood, IL, report on their long-term outcomes of salvage radiotherapy (SRT). […]
The Food and Drug Administration (FDA) has announced that it is looking into reports that Glaxo Smith Kline’s prostate drug Avodart and Merck & Co’s prostate drug Proscar may be contributing to an increase of male breast cancers. […]
Many of us once considered drinking coffee nothing but a bad habit, but now it looks as if drinking coffee is actually a good thing for us. Researchers are finding more and more benefits from drinking coffee, from preventing cancer to fighting fatigue. […]